Refractory epilepsy: Mechanisms and solutions

Expert Review of Neurotherapeutics

Volumn 6, Issue 3, 2006, Pages 397-406

  Kwan, Patrick ^a   Brodie, Martin J ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drugs; Brain stimulation; Drug resistance; Drug transporters; Epilepsy; Gene therapy; Polymers; Seizure detection; Seizures; Stem cell

Indexed keywords

ANTICONVULSIVE AGENT; ATIPAMEZOLE; BENZODIAZEPINE DERIVATIVE; BRIVARACETAM; CARBAMAZEPINE; CONANTOKIN G; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GALANIN; HARKOSERIDE; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE Y; OX 26; OXCARBAZEPINE; PARVOVIRUS VECTOR; PHENOBARBITAL; PHENYTOIN; PREGABALIN; SAFINAMIDE; SELETRACETAM; TALAMPANEL; TARIQUIDAR; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALROSEMIDE; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; AUTOANALYSIS; BIOLOGICAL ACTIVITY; BRAIN DEPTH STIMULATION; CARBOHYDRATE DIET; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CORPUS CALLOSUM TRANSSECTION; DIAGNOSTIC APPROACH ROUTE; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; DOG; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; EPILEPSY; EPILEPTOGENESIS; EXPERIMENTAL RAT; HEMISPHERECTOMY; HUMAN; HYPOTHESIS; INTRACTABLE EPILEPSY; KETOGENIC DIET; LIPID DIET; MONOTHERAPY; NEUROPATHOLOGY; NEUROSURGERY; NEUROTRANSMISSION; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PROTEIN RESTRICTION; REVIEW; TEMPORAL LOBE EPILEPSY; TREATMENT INDICATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTICONVULSANTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; ELECTRIC STIMULATION THERAPY; EPILEPSY; GENE THERAPY; HUMANS;

EID: 33645851658     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.3.397     Document Type: Review

References (86)

1. Sander JWAS, Shorvon SD. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry 61, 433-443 (1996).
2. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. 71, 576-586 (1996).
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314-319 (2000). Decribes long-term outcome of 525 newly treated epilepsy patients in a single center and clinical factors for identifying refractory epilepsy early.
4. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J. Neurol. Neurosurg. Psychiatry 75, 1376-1381 (2004).
5. Engel J Jr, Pedley TA. Introduction: what is epilepsy? In: Epilepsy: a comprehensive textbook (Volume 1). Engel J Jr, Pedley TA (Eds), Lippincott-Raven, PA, USA, 1-10 (1997).
6. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22, 489-501 (1981).
7. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical classification of epilepsies and epileptic syndromes. Epilepsia 30, 389-399 (1989).
8. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Ann. Rev. Physiol. 63, 815-846 (2001).
9. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nature Rev. Neurosci. 5, 553-564 (2004). An up-to-date authoritative review of the mechanisms of action of antiepileptic drugs.
10. Mulley JC, Scheffer IE, Petrou S, Berkovic SF. Channelopathies as a genetic cause of epilepsy. Curr. Opin. Neurol. 16, 171-176 (2003).
11. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. 90, 21-34 (2001).
12. Schachter SC. Current evidence indicates that antiepileptic drugs are anti-ictal, not antiepileptic. Epilepsy Res. 50, 67-70 (2002).
13. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42, 515-524 (2001).
14. Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101, 9861-9866 (2004).
15. Tian G-F, Azmi H, Takano T et al. Astrocytic basis of epilepsy. Nature Med. 11, 973-981 (2005). Describes the latest potentially revolutionary discovery of the role of astrocytes in the pathophysiology of seizure activity.
16. Semah F, Picot MC, Adam C et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51, 1256-1262 (1998).
17. Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 42, 357-362 (2001).
18. Wiebe S, Blume WT, Girvin JP et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med. 345, 311-318 (2001).
19. Martin RC, Kretzmer T Palmer C et al. Risk to verbal memory following anterior temporal lobectomy in patients with severe left-sided hippocampal sclerosis. Arch. Neurol. 59, 1895-1901 (2002).
20. Schachter SC. Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 59(Suppl. 4), S15-S20 (2002).
21. Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 59(Suppl. 4), S3-S14 (2002).
22. Kossoff EH. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 3, 415-420 (2004).
23. Kang HC, Kim YJ, Kim DW, Kim HD. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia 46, 272-279 (2005).
24. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46, 858-877 (2005).
25. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. (In Press) (2006).
26. Berg AT, Langfitt J, Shinnar S et al. How long does it take for partial epilepsy to become intractable? Neurology 60, 186-190 (2003).
27. Remy S, Gabriel S, Urban BW et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol. 53, 469-479 (2003).
28. A receptor subtypes in human temporal lobe epilepsy. J. Neurosci. 20, 5401-5419 (2000).
29. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301, 7-14 (2002).
30. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr. Opin. Neurol. 16, 197-201 (2003).
31. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46, 225-235 (2005).
32. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Sem. Cancer Biol. 8, 161-170 (1997).
33. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36, 1-6 (1995). The first report of upregulation of P-glycoprotein in brain tissues resected from patients with drug resistant epilepsy.
34. Sisodiya SM, Lin WR, Harding BN, Squier MC, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125, 22-31 (2002).
35. Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003).
36. Zimprich F, Sunder-Plassmann R, Stogmann E et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63, 1087-1089 (2004).
37. Tan NC, Heron SE, Scheffer IE et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63, 1090-1092 (2004).
38. Sills GJ, Mohanraj R, Butler E et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46, 643-647 (2005).
39. Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41, 81-92 (2002).
40. Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13, 129-134 (1995).
41. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. 282, 73-76 (2000).
42. + channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. 23, 393-398 (2000).
43. Biervert C, Schroeder BC, Kubisch C et al. A potassium channel mutation in neonatal human epilepsy. Science 279, 403-406 (1998).
44. Singh NA, Charlier C, Stauffer D et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nature Genet. 18, 25-29 (1998).
45. Charlier C, Singh NA, Ryan SG et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nature Genet. 18, 53-55 (1998).
46. Sólyom S, Tarnawa I. Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharm. Des. 8, 913-939 (2002).
47. Vilagi I, Takacs J, Gulyas-Kovacs A, Banczerowski-Pelyhe I, Tarnawa I. Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res. Bull. 59, 35-40 (2002).
48. Erdo F, Berzsenyi P, Andrasi F. The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia. Brain Res. Bull. 66, 43-49 (2005).
49. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61, 1-48 (2004).
50. Matagne A, Michel P, Kenda B, Klitgaard H. Seletracetam (ucb 44212), a new pyrrolidone derivative, suppresses seizures in animal models of chronic epilepsy. Epilepsia 46(Suppl. 6), 121 (2005).
51. Avendaño C, Menéndez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Medic. Chem. 9, 159-193 (2002).
52. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10, 159-165 (2003).
53. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 128, 403-411 (1999).
54. Brandt C, Bethmann K, Gastens A, Löscher W. Resistance to antiepileptic drug treatment can be counteracted by inhibition of P-glycoprotein in a rat model of temporal lobe epilepsy. Epilepsia 46(Suppl. 6), 60 (2005).
55. Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 16, 579-593 (2002). An excellent review of novel methods for antiepileptic drug delivery under investigation.
56. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51, 31-71 (2002).
57. Barton ME, White HS. The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res. 59, 1-12 (2004).
58. Lu XC, Williams AJ, Wagstaff JD, Tortella FC, Hartings JA. Effects of delayed intrathecal infusion of an NMDA receptor antagonist on ischemic injury and peri-infarct depolarizations. Brain Res. 1056, 200-208 (2005).
59. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug Dis. 4, 145-160 (2005).
60. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2, 99-107 (2005).
61. Mori N, Kurokouchi A, Osonoe K et al. Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Brain Res. 703, 184-190 (1995).
62. Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurg. 41, 44-48 (1997).
63. Boison D, Scheurer L, Tseng JL, Aebischer P, Mohler H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp. Neurol. 160, 164-174 (1999).
64. Kokaia M, Aebischer P, Elmer E et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp. Brain Res. 100, 385-394 (1994).
65. Tamargo RJ, Rossell LA, Kossoff EH et al. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res. 48, 145-155 (2002).
66. Hamani C, Hodaie M, Lozano AM. Present and future of deep brain stimulation for refractory epilepsy. Acta Neurochir. 147, 227-229 (2005).
67. Velasco F, Velasco M, Velasco AL, Jimenez F, Marquez I, Rise M. Electrical stimulation of the centromedian thalamic nucleus in control of seizures: long-term studies. Epilepsia 36, 63-71 (1995).
68. Kerrigan JF, Litt B, Fisher RS et al. Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsy. Epilepsia 45, 346-354 (2004).
69. Benabid AL, Minotti L, Koudsie A, de Saint Martin A, Hirsch E. Antiepileptic effect of high-frequency stimulation of the subthalamic nucleus (corpus luysi) in a case of medically intractable epilepsy caused by focal dysplasia: a 30-month follow-up: technical case report. Neurosurgery 50, 1385-1391 (2002).
70. Velasco F, Carrillo-Ruiz JD, Brito F et al. Double-blind, randomized controlled pilot study of bilateral cerebellar stimulation for treatment of intractable motor seizures. Epilepsia 46, 1071-1081 (2005).
71. Yonch K, Boon P, Achten E et al. Long term amygdalohippocampal stimulation for refractory temporal lobe epilepsy. Ann. Neurol. 52, 556-565 (2002).
72. Theodore WH, Fisher RS. Brain stimulation for epilepsy. Lancet Neurol. 3, 111-118 (2004). An up-to-date review of the current clinical and research status of brain stimulation for the treatment of drug-resistant epilepsy.
73. Stein AG, Eder HG, Blum DE, Drachev A, Fisher RS. An automated drug delivery system for focal epilepsy. Epilepsy Res. 39, 103-114 (2000).
74. Fountas KV, Smith JR, Murro AM, Politsky J, Park JD, Jenkins PD. Implantation of a closed-loop stimulation in the management of medically refractory focal epilepsy. Stereotact. Funct. Neurosurg. 83, 153-158 (2005).
75. Litt B, Echauz J. Prediction of epileptic seizures. Lancet Neurol. 1, 22-30 (2002).
76. Shetty AK, Turner DA. Fetal hippocampal grafts containing CA3 cells restore host hippocampal glutamate decarboxylase-positive interneuron numbers in a rat model of temporal lobe epilepsy. J. Neurosci. 20, 8788-8801 (2000).
77. Löscher W, Ebert U, Lehmann H et al. Seizure suppression in kindling epilepsy by grats of fetal GABAergic neurons in rat substantia nigra. J. Neurosci. Res. 51, 196-209 (1998).
78. Huber A, Padrun V, Déglon N et al. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc. Natl Acad. Sci. USA 98, 7611-7616 (2001).
79. Güttinger M, Fedele D, Koch P et al. Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. Epilepsia 46, 1162-1169 (2005).
80. Chu K, Kim M, Jung KH et al. Human neural stem cell transplantation reduces spontaneous recurrent seizures following pilocarpine-induced status epilepticus in adult rats. Brain Res. 1023, 213-221 (2004).
81. Haberman RP, Samulski RJ, McCown TJ. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nature Med. 9, 1076-1080 (2003).
82. Richichi C, Lin E-J D, Stefanin D et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 24, 3051-3059 (2004).
83. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 60(Suppl. 4), S2-S12 (2003).
84. Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 45, 895-907 (2004).
85. Brodie MJ, Yuen AWC and the 105 Study Group. Lamotrigine substitution study: synergism with sodium valproate? Epilepsy Res. 26, 423-432 (1997).
86. Pisani F, Otero G, Russo MF. Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40, 1141-1146 (1999).